Grifols S.A. (0RDU)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 10.07 |
|---|---|
| 52-week range | 8.39 – 11.61 |
| Return, 1 month / 3 months | +3.9% / +7.0% |
| Return, 1 year / 3 years | −10.7% / +2.1% |
| Trend | Uptrend |
| RSI (14) | 57 |
| Volatility (1 year) | 28.4% |
| Worst drawdown (1 year) | -25.3% |
| Average daily value traded | 0.32M EUR |
| Dividend yield | 0.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Grifols is a pharmaceutical company based in Spain that makes medicines from human blood plasma. It collects plasma at its own donation centres and processes it into therapies such as immunoglobulins, albumin and clotting factor products, which are used to treat immune deficiencies, bleeding disorders and other conditions. Its customers are mainly hospitals, clinics and healthcare systems, and it also supplies diagnostic instruments and services for blood testing in laboratories and transfusion centres.
Grifols S.A. trades under the code 0RDU on the London Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Grifols S.A. (0RDU) trades on the London Exchange in UK. It last closed at EUR 10.07 on 21 October 2026.
Its price-based Market X-Ray is 53 out of 100 (a fair price profile), ranking 1,902 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 10.7% and over the last three months it rose 7.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 57 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.9% | ||
| From 52-week high | -12.3% | ||
| Momentum | 56 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 7.0% | ||
| 6-month return | 13.0% | ||
| 12-month return, skipping the last month | -14.1% | ||
| Stability (higher is calmer) | 63 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.3% | ||
| Liquidity | 41 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.32M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 23 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.7% | ||
| Years with dividends | 2 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.3% |
|---|---|
| 1 month | +3.9% |
| 3 months | +7.0% |
| 6 months | +13.0% |
| 1 year | −10.7% |
| 3 years | +2.1% |
| 5 years | −49.8% |
Signals
| 50-day / 200-day average | 9.84 / 9.70 |
|---|---|
| Golden / death cross (60 days) | Golden, 22 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.22 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Jun 2026 | EUR 0.0667 |
| 11 Aug 2025 | EUR 0.1215 |
| 3 Jun 2021 | EUR 0.2951 |
| 26 Oct 2020 | EUR 0.1309 |
| 2 Dec 2019 | EUR 0.1620 |
| 7 Jun 2019 | EUR 0.1176 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.